Related Experiment Video
Updated: May 17, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
Cell-type-specific APOE4 cascade across the Alzheimer's disease continuum
David Shostak1, Zherui Liang1, Yadong Huang2
1Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA, USA.
Neuron
|May 15, 2026
Summary
Apolipoprotein E4 (APOE4) drives Alzheimer's disease (AD) progression. This model shows APOE4 affects neurons early and glia later, impacting AD stages and suggesting targeted therapies.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Apolipoprotein E4 (APOE4) is a major genetic risk factor for Alzheimer's disease (AD).
- AD progresses through preclinical, prodromal, and dementia stages, with APOE4 contributing detrimentally across this continuum.
- Understanding the timing and cellular targets of APOE4 is crucial for developing effective interventions.
Purpose of the Study:
- To synthesize current findings on APOE4's role in AD progression.
- To propose a temporal model illustrating cell-type-specific APOE4 effects across the AD continuum.
- To identify potential therapeutic strategies targeting APOE4-driven mechanisms.
Main Methods:
- Review and synthesis of existing scientific literature on APOE4 and AD.
- Development of a temporal model linking APOE4 expression to AD pathological stages.
- Analysis of cell-type-specific effects of APOE4 (neuronal and glial).
Main Results:
- Age-associated stress upregulates neuronal APOE4, causing early deficits in preclinical AD.
- Neuronal damage from APOE4 triggers a glial response, amplifying neurodegeneration.
- Glial APOE4 further exacerbates neurodegeneration, accelerating prodromal and dementia stages of AD.
Conclusions:
- The proposed model highlights the temporal and cellular dynamics of APOE4's detrimental effects in AD.
- Therapeutics targeting APOE4 should be tailored to specific disease stages and cell types.
- This framework aids in developing stage- and cell-type-specific treatments for APOE4-related AD.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...